Prognostic value of inflammation-immunity-nutrition score in cancer patients: a meta-analysis.

Ann MedAug 20, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Kaixiang He, Yunfei Li, Jing Luo et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the prognostic value of the inflammation-immunity-nutrition score (IINS) in cancer patients, analyzing data from 3,950 participants across eight studies. The findings indicate that elevated IINS is significantly associated with poorer overall survival (HR = 2.13) and shorter progression-free survival (HR = 1.95), suggesting its potential as a prognostic biomarker in oncology.

Key findings

  • Elevated IINS was associated with poorer overall survival (HR = 2.13, 95% CI: 1.56-2.90, p < 0.001).
  • Higher IINS categories correlated with progressively less favorable survival outcomes.
  • Shorter progression-free survival was linked to elevated IINS (HR = 1.95, 95% CI: 1.65-2.31, p < 0.001).

Why it matters

Understanding the prognostic implications of IINS can help clinicians assess cancer patient outcomes more effectively. This score may provide additional insights into patient management and treatment planning.

What to keep in mind

The evidence is predominantly retrospective and derived entirely from Chinese populations, limiting generalizability.

Source

PubMed · PMID 42622233Free full text on PubMed Central

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.